Harousseau: Maintenance therapy in multiple myeloma

Maintenance therapy in multiple myeloma


The treatment of multiple myeloma (MM) has changed dramatically in the past twenty years with the introduction of high-dose therapy plus autologous stem-cell transplantation (ASCT) in younger patients and, more recently, of three novel agents (thalidomide, bortezomib, and lenalidomide).

When conventional chemotherapy was the only available possibility, complete responses (CR) were very rare and the objective of maintenance was to prolong remission duration by continuing the same type of treatment that induced the initial response. With recent therapeutic improvements, CR achievement becomes a realistic goal that, in most cases, is significantly correlated with the outcome.1 Therefore, both the nature and the impact of maintenance therapy have changed. Maintenance therapy is based currently on novel agents, and its objective is not only to control the clone but also to further decrease the tumor burden and improve the quality of response.

A number of randomized studies show a benefit from maintenance therapy with novel agents (until now, mostly thalidomide), at least in terms of response rate and progression-free survival (PFS). However, there is still a debate as concerns the impact on overall survival (OS) and the optimal administration of maintenance therapy.

Maintenance therapy in the pre-thalidomide era

In patients initially treated with conventional chemotherapy, maintenance chemotherapy has failed to demonstrate any significant benefit.2,3 Therefore, the recommendation was to stop chemotherapy once stable response had been achieved (the so-called plateau phase).

One study showed a survival advantage for patients receiving alternate-day prednisone maintenance therapy at a dose of 50 mg when compared with 10 mg after standard induction chemotherapy.4

In the nineteen-eighties α-interferon maintenance therapy represented a great hope. Following the initial randomized study showing prolonged remissions with α-interferon maintenance in patients responding to conventional induction therapy,5 a number of randomized trials were performed but their results were controversial.6 Two meta-analyses of randomized trials showed that with interferon maintenance, time to PFS and OS was increased by four to seven months.7,8 However, most investigators considered that the benefit was small and needed balancing against cost and potential toxicity of prolonged treatment with α-interferon.

In addition, α-interferon has been used after ASCT, with the hypothesis that it might be more effective in patients with minimal residual disease. In a retrospective analysis of the European Bone Marrow and Blood Transplant Registry, interferon maintenance was associated with improved PFS and OS in patients responding to high-dose therapy.9 However, two randomized trials failed to confirm this result.10,11

Thalidomide as maintenance therapy after autologous stem-cell transplantation

When thalidomide maintenance therapy was first introduced in the field of ASCT for MM, the median duration of response did not exceed three years and almost all patients did relapse ultimately.12 Six randomized trials have evaluated the impact of thalidomide maintenance after ASCT in MM.1217 However, these trials differed in their design and in the dose and duration of thalidomide maintenance (Table 1).

Table 1

Post-ASCT maintenance with thalidomide: randomized studies.

Author Induction ASCT Thalidomide administration Design
Attal et al.12 No Thal Double Starting dose 400 mg/d until relapse After ASCT (if no progression)
No treatment vs. Thal Pamidronate
Barlogie et al.13 50% Thal Double Starting dose 400 mg/d until relapse Initial randomization Thal vs. no Thal
Abdelkefi et al.14 Thal Single Thal vs. double 100 mg/d for 6 months After ASCT
Spencer et al.15 No Thal Single 20 mg/d for 1 year After ASCT (if no progression)
Morgan et al.16 50% Thal Single 100 mg/d until relapse After ASCT
Lokhorst et al.17 50% Thal Double 200 mg/d until relapse Initial randomization
TAD Thal

[i] ASCT, autologous stem cell transplantation; Thal, thalidomide; d, day; TAD, thalidomide adriamycin dexametasone; VAD, vincristine adriamycin dexamethasone; IFN, interferon.

In two of these studies, patients were randomized initially to receive thalidomide throughout their treatment (both before and after ASCT).13,17 Therefore, the putative impact of thalidomide was not expected to be a result of the maintenance effect only.

In the other four studies, patients were randomized after ASCT to receive either thalidomide or not. While in two of these trials the control group was to receive no further treatment,12,16 in the Tunisian study by Abdelkefi et al. (2008), thalidomide maintenance was compared to a second ASCT,14 and in the Australian study by Spencer et al. (2009) the combination of thalidomide plus alternate-day prednisone was compared to the administration of prednisone alone.15

In two of these trials, patients were randomized only if they were not progressing after induction treatment plus ASCT,12,15 while in the other two studies, all patients were randomized, whatever the degree of post-ASCT response.14,16 Finally, in the French and Australian studies by Attal et al. (2006) and Spencer et al. (2009), respectively,12,15 thalidomide was not used during induction treatment. In the British study by Morgan et al. (2008), there was an initial randomization at diagnosis (thalidomide versus no thalidomide),16 and in the Tunisian study by Abdelkefi et al. (2008), all patients received thalidomide plus dexamethasone as induction treatment prior to ASCT.14

In four of these six trials, thalidomide was prescribed until relapse or until severe adverse event, while in the studies by Abdelkefi et al. (2008) and Spencer et al. (2009), the duration of thalidomide was fixed (six months in the Tunisian study and 12 months in the Australian study).14,15 The daily dose of thalidomide varied from 100 mg/day14 to an initial dose of 400 mg/day in the first two of the six studies.12,13 Despite these disparities, all six studies showed a benefit in favor of thalidomide in terms of response rate (CR, or greater than or equal to very good partial remission and PFS) (Table 2).

Table 2

Results of randomized studies on post-ASCT maintenance with thalidomide.

Author N. of
PFS or EFS OS initial
OS updated
Barlogie et al.13 668 42 m 62% vs. 43%
5-year EFS
56% vs. 44%
5-year OS
65% vs. 65%
Attal et al12 597 40 m *67% vs. 55% or 57%
3-year EFS
52% vs. 37%
87% vs. 75%
Abdelkefi et al.14 195 33 m *68% vs. 54%
3-year PFS
85% vs. 57%
85% vs. 65%
Spencer et al.15 269 3 y 65% vs. 44%*
3-year PFS
42% vs. 23%
86% vs. 75%
Morgan et al.16 820** 32 m NA Better in patients
with < VGPR
Median OS
Lokhorst et al.17 556 52 m *66% vs. 54%
Median EFS
34 m vs. 22 m
73 m vs. 60 m

* complete response;

very good partial response (VGPR);

** including patients receiving non-intensive induction;

{ label (or @symbol) needed for fn } ASCT, autologous stem cell transplantation; PFS, progression-free survival; EFS, event-free survival; OS, overall survival; NS, not significant; m, months; y, years; ND, not done; NA, not available.

Results are not that clear-cut as regards OS. While in the initial publication of the French and Tunisian studies12,14 OS was significantly longer in the thalidomide trials, with longer follow-up this survival advantage disappeared, and Aldelkefi et al. (2009) did publish a retraction recently.18

On the contrary, the first publication from the Arkansas group showed no significant difference in OS between the two groups, because of a shorter OS after relapse in patients initially treated with thalidomide.11 However, with a longer follow-up, the OS curves diverge after five years.19 A second report of the same trial, showed a trend in favor of thalidomide and a significant benefit in the subgroup of patients with karyotypic abnormalities.13 In the Dutch (Lokhorst et al., 2008) and British ) and British (Morgan et al., 2008) studies, the PFS benefit did not translate into a significant OS benefit, again because of a shorter OS after relapse in the thalidomide group.16,17

How can we analyze these differences?

The first message is that OS data should not be analyzed and published too early. In the past the only possibility at relapse was conventional chemotherapy. Currently we have more possibilities (e.g., ASCT, thalidomide and lenalidomide, bortezomib), and survival after relapse may be longer than duration of first response. Since it is possible to achieve median OS of more than or equal to five years now, OS should not be analyzed before at least five-year median follow-up time.

Secondly, OS obviously depends on salvage treatments. If thalidomide is prescribed until relapse or severe toxicity, one can imagine that thalidomide should not be used at relapse. Therefore, more patients receive thalidomide at relapse in the no-thalidomide trials, and the design of these studies is rather early (up front) thalidomide versus late (at relapse) thalidomide. This was actually the case with ASCT: in randomized trials comparing ASCT and conventional chemotherapy, ASCT was superior in terms of PFS but not always in terms of OS, partly because patients in the conventional chemotherapy group could receive ASCT at relapse.20 A randomized study comparing early versus late ASCT showed no significant difference in terms of OS.21

Moreover, the risk of thalidomide-induced peripheral neuropathy is clearly related to the cumulative dose, and prolonged exposure carries the risk of severe neuropathy, precluding or limiting the use of bortezomib. Prolonged exposure to thalidomide might select clones resistant not only to thalidomide but also to other agents. We already know that lenalidomide is less effective in patients resistant to thalidomide than in thalidomide-naïve patients.22

Finally, salvage treatment depends on the availability of novel agents. When the British trial by Morgan et al. (2008) was performed, there was a limited access to bortezomib, and lenalidomide was not available except for clinical trials. Therefore there were more therapeutic possibilities (including thalidomide) at relapse in the no-thalidomide group.

These considerations clearly raise the issue of the optimal duration of maintenance therapy. Should it be fixed as in the Tunisian or Australian studies,14,15 or unlimited as in the other four studies?12,13,16,17 The theoretical interest of prolonged maintenance is to further improve the level of tumor burden reduction, hence prolonging PFS but, on the other hand, this benefit might be hampered by reduced salvage possibilities, hence a shorter OS after relapse. A randomized study addressing this question might be extremely useful.

Additional questions

What is the optimal schedule of administration?

In the first two studies by Attal et al. (2006) and Barlogie et al. (2006), the initial daily dosage was high (400 mg) and the duration of treatment was unlimited, which explains the high incidence of severe neuropathy (Grade ≥3), as well as the percentage of patients who discontinued treatment because of toxicity.12,13 Although no randomized study has compared different schedules of administration, doses of 100 mg or 200 mg/day during 6–12 months appear to be effective and better tolerated.13,14

Is thalidomide maintenance useful for all patients, and are we able to predict patients who will benefit from maintenance therapy?

Unfortunately there is no clear response to this question. In the French study by Barlogie et al. (2006), patients with del13 apparently did not benefit from thalidomide maintenance, but at the time of this trial other abnormalities that are frequently associated with del(13), such as t(4;14) or 17p del, were not routinely studied.12 We know now that the negative prognostic impact of del(13) is mostly a result of these two additional abnormalities.23 We have no published data on the impact of thalidomide in this subgroup of patients with these poor-risk abnormalities, although in a preliminary report (Lokhorst et al., 2008), thalidomide appeared to perform poorly in patients with del(17p).17

In the updated analysis of the Arkansas study by Adelkefi et al. (2009), thalidomide significantly improved OS of patients with cytogenetic abnormalities as defined by conventional karyotyping.18 This heterogeneous subgroup of patients generally is considered as poor-risk, since the possibility of studying mitoses is associated with a more proliferative disease.

Finally, in the studies by Attal et al. (2006) and Morgan et al. (2008), only patients who did not achieve at least a very good partial response (VGPR) after transplant benefitted from thalidomide maintenance,12,16 but this was not confirmed by Spencer et al. (2009).15

Does thalidomide act as a maintenance or consolidation therapy?

In all the studies reviewed, the PFS prolongation was associated with a CR or CR/VGPR increase. Moreover, the fact that patients who showed CR after ASCT did not benefit from thalidomide in at least two of the studies could mean that thalidomide might act more by increasing the post-ASCT CR rate than by controlling the residual clone. In other words, post-ASCT thalidomide might be considered as a consolidation therapy, and might be administered with the objective of further decreasing the tumor burden. If this is true, we still have to determine the optimal level of response. Is CR with negative immunofixation the requested level or should we try to obtain higher levels of response (stringent response, immunophenotypic response, or even molecular response)?

This important question should be addressed in future trials. To date, Paiva et al. (2008) have shown that immunophenotypic CR, as assessed by multi-parameter flow cytometry, is associated with a better outcome than CR as defined only by immunofixation.24

Other novel agents as maintenance therapy after autologous stem-cell transplantation

Lenalidomide, which is better tolerated than thalidomide and can be prescribed safely for long periods of time, appears to be an ideal candidate for maintenance therapy. However, this agent is more myelotoxic than thalidomide and the optimal dose of lenalidomide after high-dose therapy is not known. Two large randomized trials from the Intergroupe Francophone du Myelome (IFM ) and the Cancer and Acute Leukemia Group B (CALGB) groups have tested lenalidomide as maintenance after ASCT, but results of these studies are not available.

In addition, bortezomib has been evaluated in this setting by Morgan et al. (2008) and Paiva et al. (2008).16,24 Since bortezomib is associated with a high incidence of peripheral neuropathy when used on a bi-weekly schedule at a dose of 1.3 mg/m2, the issue of the toxicity/efficacy ratio is crucial.

If the objective of post-ASCT therapy is to increase the level of response with a consolidation effect further, short-term treatment with combinations of novel agents might be attractive as well. Ladetto et al. (2008) recently showed encouraging results with four courses of consolidation treatment with bortezomib-thalidomide-dexamethasone.25 In this study, six out of 24 patients, who were at least in VGPR after ASCT, achieved molecular remissions and none of them had a relapse with a median follow-up of 26 months.

Novel agents as maintenance therapy after allogeneic stem-cell transplantation

Currently, allogeneic stem-cell transplantation (allo-SCT) following a myeloablative conditioning regimen has almost been abandoned in MM because of excessive toxicity.26 Reduced-intensity conditioning is associated with reduced transplant-related mortality but with increased relapse rate compared to standard allo-SCT.27 In order to decrease the relapse rate, a strategy with tandem ASCT-reduced intensity conditioning allo-SCT is currently proposed. However, relapses remain frequent, especially in the absence of chronic-graft versus host disease.26 Therefore, post-transplant immunotherapy with donor-lymphocyte infusions and/or novel agents has been tested with the objective of upgrading the level of response. In a preliminary experience, Kroger et al. (2009) have proposed novel agents (thalidomide, bortezomib, or lenalidomide) to patients who were not in CR after allo-SCT and donor lymphocyte infusions.28 They could convert partial remission to CR in 59% of patients and to molecular remissions in 50% of patients.

Thalidomide maintenance therapy after non-intensive induction treatment

In a recent trial Ludwig et al. (2009) evaluated thalidomide plus interferon compared with interferon alone in 135 elderly patients with at least stable disease after induction treatment with either thalidomide dexamethasone or melphalan-prednisone (MP). Athough PFS was significantly longer in the thalidomide group (24 months versus 13 months, p>0.024), OS was similar in both groups.29

Five randomized trials have compared MP and MP plus thalidomide (MPT) as the primary treatment in elderly patients.3035 Although the design of these studies and the inclusion criteria were slightly different, all five studies have shown a benefit of MPT in terms of response rate, and PFS was significantly longer in the MPT groups of four out of five studies (Table 3).

Table 3

Melphalan-prednisone versus melphalan-prednisone-thalidomide studies: absence of impact of maintenance with thalidomide on overall survival.

Author Palumbo et al.31 Facon et al.32 Hullin et al.33 Golbrandsen et al.34 Wijermans et al.35
Number of patients (MPT) 331 (167) 447 (125) 232 (113) 362 (182) 301 (152)
Age (yrs) 72 69 78.5 74.5 72
Median range 6085 6575 7691 4992 -
WHO (%) 5 8 7 30 4
MPT regimen
Number of cycles 6 12 12 Until plateau Until plateau
M dosing 4 mg/m2 0.25 mg/kg 0.2 mg/kg 0.25 mg/kg 0.2 mg/kg
d17 d14 d14 d14 d15
T dosing 100 mg/d Up to 400 mg/d 100 mg/d Up to 400 mg/d 200 mg/d
Maintenance YES NO NO YES YES
Outcome (MPT vs. MP)
Response rate (%) 76 vs. 48* 76 vs. 35* 62 vs. 30* 49 vs. 28* 66 vs. 47*
PFS (m) 22 vs. 14.5* 27.5 vs. 18* 24 vs. 19* 20 vs. 18 14 vs. 10*
OS (m) 45 vs. 47.5 51.5 vs. 33* 45 vs. 27.5* 29 vs. 33 37 vs. 30

[i] Significant difference, (p<0.005);

[ii] d, day; M, melphalan; P, prednisone; T, thalidomide; MP, melphalan-prednisone; WHO, World Health Organization; OS, overall survival; PFS, progression-free survival.

However, in only two studies this benefit translated into a significantly longer survival,32,33 and in these two studies there was no maintenance while in the other three trials there was a maintenance with thalidomide alone in the MPT groups. In the Italian study by Palumbo et al. (2008), the shorter survival after relapse in the MPT group might have been explained by a lower percentage of patients receiving thalidomide as salvage treatment at relapse.31 Since the three studies were not designed to address the question of maintenance, it is not possible to consider that the lack of survival benefit in the MPT group is related to maintenance thalidomide. However, one can conclude from these studies that there is no evidence that maintenance thalidomide is useful in elderly patients initially treated with MPT. Until now, in elderly patients, available data do not show a benefit from maintenance treatment with thalidomide, at least in terms of OS. At least two randomized studies addressing the question of maintenance treatment with lenalidomide in elderly patients are ongoing.


In younger patients, post-ASCT maintenance therapy with thalidomide appears to increase tumor burden reduction further, which translates in prolonged PFS. However, the benefit in terms of OS is not clear and many questions remain regarding the respective role of consolidation versus maintenance, the optimal drug and the optimal schedule of administration and duration of treatment, as well as the characteristics of patients who may benefit from this approach. In elderly patients there is currently no evidence that maintenance treatment improves OS.



J-L Harousseau, M Attal, H Avet-LoiseauThe role of complete response in multiple myelomaBlood2009Jul28[Epub ahead of print]


R Alexanian, S Balzerzac, A HautRemission maintenance therapy for multiple myelomaArch Intern Med197513514752


A Belch, W Shelley, D BergsagelA randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patientsBr J Cancer198857949


JR Berenson, JJ Crowley, TM GroganMaintenace therapy with alternate-day prednisone improves survival in multiple myeloma patientsBlood20029931638


F Mandelli, G Avvisati, S AmadoriMaintenance therapy with recombinant alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapyN Engl J Med199032214304


R Bataille, J-L HarousseauMultiple MyelomaN Engl J Med1997336165764


E Fritz, H LudwigInterferon-α treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948patients Ann Oncol200011142736


Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patientsBr J Haematol2001113102034


B Bjorkstrand, H Svensson, H Goldschmidtα-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the EBMTBone marrow transplant2001275115


D Cunningham, R Powles, J MalpasA randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma:long-term resultsBr J Haematol1998102195202


B Barlogie, RA Kyle, KC AndersonStandard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321J Clin Oncol20062492936


M Attal, J-L Harousseau, S LeyvrazMaintenance therapy with thalidomide improves survival in multiple myeloma patientsBlood200615328994


B Barlogie, G Tricot, E AnaissieThalidomide and hematopoietic stem cell transplantation for multiple myelomaN Engl J Med2006354102130


A Abdelkefi, S Ladeb, L TorjmanSingle autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trialBlood2008111180510


A Spencer, HM Prince, A RobertsConsolidation therapy with thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single ASCT procedureJ Clin Oncol200927178893


GJ Morgan, GH Jackson, FE DaviesMaintenance thalidomide may improve progression free but not overall survival: results from the Myeloma IX maintenance randomisationBlood2008112656


HM Lokhorst, B van der Holt, S ZweegmannFinal analysis of Hovon 50 randomized Phase III study on the effect of thalidomide combined withadriamycin, dexamethasone and high-dose melphalan in patients with multiple myelomaBlood2008112461


A Abdelkefi, S Ladeb, L TorjmanRetractation of reference 14Blood20091136265


B Barlogie, M Pinedda-Roman, F van RheeThalidomide arm of Total therapy 2 improves complete remission and survival in myeloma patients with metaphase cytogenetic abnormalitiesBlood2008112311521


J-L Harousseau, P MoreauAutologous stem-cell transplantation in multiple myelomaN Engl J Med2009360264554


JP Fermand, P Ravaud, S ChevretHigh-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? Results of a multicenter sequential randomized trialBlood19989231316


M Wang, MA Dimopoulos, C ChenLenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureBlood2008112444551


H Avet-Loiseau, M Attal, P MoreauGenetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeBlood2007109348995


B Paiva, MB Vidriales, J CerveroMultiparameter flow cytometry is the most relevant prognostic factor relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBlood2008112401723


M Ladetto, G Pagliano, S FerreroMajor shrinking of residual tumor cell burden and achievement of molecular remissions in myeloma patients undergoing post-transplant consolidation with bortezomib, thalidomide and dexamethasone: aqualitative and quantitative PCR studyBlood20081123683


J-L HarousseauThe allogeneic dilemmaBone Marrow Transplant22074011238


C Crawley, S Iacobelli, B BjorkstrandReduced-intensity conditioning for mylome: lower non-relapse mortality but higher relapse rates compared with myloablative conditioningBlood2007109358894


N Kroger, A Badbaran, M LioznovPost-transplant immunotherapy with donor-lymphocyte infusions and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myelomaExp Hematol2009377918


H Ludwig, A Zdenek, E TothovaThalidomide/Interferon versus interferon maintenance after thal/dex versus MPclin Lymphoma Myeloma2009147147


A Palumbo, S Bringhen, T CaravitaOral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan alone in elderly patients with MM: randomized controlled trialLancet200636782531


A Palumbo, S Bringhen, AM LiberatiOral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trialBlood2008112310714


T Facon, JY Mary, C HulinMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trialLancet2007370120918


C Hulin, T Facon, P RodonEfficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 TrialJ Clin Oncol2009May18[Epub ahead of print]


N Gulbrandsen, A Waage, P GimsingA randomised placebo controlled study with melphalan/prednisone versus melphalan/prednisone/thalidomide: quality of life and toxicityHaematologica200893(S1)8484(abstract 209)


PW Wijermans, S Zweegman, M van Marwijk KooyMP versus MPT in elderly myeloma patients: the final outcome of the HOVON-49 studyclin Lymphoma Myeloma2009(S14)(abstract 116)

Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c)
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185